超越NLRP3:NLR相关自身炎症性疾病谱系的扩展
不同变异组呈现不同表型模式,约三分之一患者对秋水仙碱有效,另三分之一需IL-1阻断治疗。
要点
- 非NLRP3的NLR变异患者呈现广泛重叠的自身炎症表型,黏膜皮肤受累常见。
- NLRP1变异常伴FMF样特征,NLRC4变异可伴胃肠道受累及不典型皮疹。
- 约三分之一患者对秋水仙碱有效,另三分之一需IL-1阻断治疗。
核心结论
- 携带罕见非NLRP3 NLR变异的患者表现出广泛且重叠的系统性自身炎症表型,常以黏膜皮肤受累为特征。
研究设计与样本
- 回顾性分析转诊为系统性自身炎症性疾病且携带NLR变异的患者,所有患者接受靶向二代测序,变异按ACMG标准解读。
主要发现
- NLRP1变异常与FMF样特征相关,包括反复发热和浆膜炎,偶伴自身免疫特征。
- NLRP7变异表现为反复发热发作伴黏膜皮肤受累。
- NLRP12变异典型表现为周期性发热综合征和斑丘疹或结节性红斑样皮损。
- NLRC4变异表现为发作性系统性炎症伴胃肠道受累及不典型皮肤表现,包括丹毒样红斑和血管性水肿。
关键数值与推荐
- 约三分之一患者对秋水仙碱有应答,另三分之一需要IL-1阻断治疗。
- 部分患者中鉴定出共存MEFV变异。
临床怎么用
- 对于表现不典型的炎症患者,除MEFV外应考虑扩展遗传学评估以纳入NLR家族基因。
- 携带非NLRP3 NLR变异的患者可尝试秋水仙碱或IL-1阻断治疗,但需进一步功能研究明确变异的致病意义。
局限性
- 本研究为描述性观察,需进一步功能研究以阐明这些变异的致病意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gain-of-function mutations in NLRP3 represent the prototypical cause of inflammasome-driven systemic autoinflammatory diseases (SAIDs). Other members of the nucleotide-binding domain and leucine-rich repeat-containing (NLR) family, including NLRP1, NLRP7, NLRP12, and NLRC4, may also contribute to systemic inflammatory phenotypes. We aimed to characterize patients carrying NLR-variants. METHODS: Patients referred for SAIDs and harbouring NLR-variants were retrospectively analysed. All patients underwent targeted next-generation sequencing and variants were interpreted according to ACMG criteria. Demographics, clinical manifestations, laboratory, and treatment data were recorded. RESULTS: Thirty-three patients (70% female; age 19-62 years) were included. Recurrent fever was the predominant manifestation and frequently accompanied by musculoskeletal symptoms and prominent mucocutaneous findings, including erythematous and urticarial rashes, erythema nodosum-like lesions, oral aphthae, and conjunctivitis. Distinct phenotypic patterns were observed across variant groups. NLRP1 variants were often associated with FMF-like features, including recurrent fever and serositis, occasionally with autoimmune features. NLRP7 variants presented with recurrent febrile episodes with mucocutaneous involvement. NLRP12 variants typically presented with periodic fever syndromes and maculopapular or erythema nodosum-like lesions. NLRC4 variants were observed with episodic systemic inflammation with gastrointestinal involvement and atypical cutaneous manifestations including erysipelas-like erythema and angioedema. Coexisting MEFV variants were identified in a subset. Approximately one-third responded to colchicine, whereas another third required IL-1 blockade. CONCLUSION: Patients carrying rare non-NLRP3 NLR variants demonstrated a broad and overlapping spectrum of systemic autoinflammatory phenotypes, frequently marked by mucocutaneous involvement. These descriptive observations highlight the need for further functional studies to clarify the pathogenic significance of these variants and importance of expanded genetic evaluation beyond MEFV in patients with atypical inflammatory presentations and describe clinical responses to colchicine and IL-1 inhibition in a subset of patients.
引用
- Deniz R, Tansu Yavuz C, Aydın Gümüş A, et al. Beyond NLRP3: expanding the spectrum of NLR-associated autoinflammatory diseases. Rheumatology (Oxford). 2026. PMID: 42755046. doi:10.1093/rheumatology/keag518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。